Evidence map›Paper›PMID 38798338›Full record

ArticlebioRxiv : the preprint server for biology2024

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

William C Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered Pita-Juarez, Dimitra Karagkouni, Chaitanya R Acharya, Marina E Michaud, Mark Hamilton, Shivani Nanda, Yizhe Song and 51 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

61 authors.

William C PilcherCoultier Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Lijun YaoDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Edgar Gonzalez-KozlovaHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yered Pita-JuarezBeth Israel Deaconess Medical Center, Boston, MA, USA.
Dimitra KaragkouniBeth Israel Deaconess Medical Center, Boston, MA, USA.
Chaitanya R AcharyaMMRF, Norwalk, CT, USA.
Marina E MichaudDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Mark HamiltonMMRF, Norwalk, CT, USA.
Shivani NandaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Yizhe SongDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Kazuhito SatoDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Julia T WangDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Sarthak SatpathyDepartment of Biomedical Informatics, Emory School of Medicine, Atlanta, GA, USA.
Yuling MaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Jessica SchulmanMMRF, Norwalk, CT, USA.
Darwin D'SouzaHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reyka G JayasingheDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Giulia CheloniBeth Israel Deaconess Medical Center, Boston, MA, USA.
Mojtaba BakhtiariDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Nick PabustanMMRF, Norwalk, CT, USA.
Kai NieHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jennifer A FoltzDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Isabella SaldarriagaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Rania AlaaeldinDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Eva LepistoMMRF, Norwalk, CT, USA.
Rachel ChenHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mark A FialaBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Beena E ThomasDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
April CookMMRF, Norwalk, CT, USA.
Junia Vieira Dos SantosTisch Cancer Institute, Department of Immunology and Immunotherapy, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
I-Ling ChiangDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Igor FigueiredoHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Julie FortierBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Michael SladeBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Stephen T OhDivision of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Michael P RettigDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Emilie AndersonMayo Clinic, Rochester, MN, USA.
Ying LiMayo Clinic, Rochester, MN, USA.
Surendra DasariMayo Clinic, Rochester, MN, USA.
Michael A StrausbauchMayo Clinic, Rochester, MN, USA.
Vernadette A SimonMayo Clinic, Rochester, MN, USA.
Immune Atlas Consortium
Adeeb H RahmanHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8620-3161
Zhihong ChenHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7403-7015
Alessandro LaganaTisch Cancer Institute, Department of Immunology and Immunotherapy, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
John F DiPersioDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Jacalyn RosenblattBeth Israel Deaconess Medical Center, Boston, MA, USA.
Seunghee Kim-SchulzeHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Madhav V DhodapkarDepartment of Hematology Oncology, Emory School of Medicine, Atlanta, GA, USA.
Sagar LonialDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Shaji KumarMayo Clinic, Rochester, MN, USA.
Swati S BhasinDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-5172-420X
Taxiarchis KourelisMayo Clinic, Rochester, MN, USA.
Ravi VijBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
David AviganBeth Israel Deaconess Medical Center, Boston, MA, USA.
Hearn J ChoMMRF, Norwalk, CT, USA.
George MulliganMMRF, Norwalk, CT, USA.
Li DingDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Sacha GnjaticHuman Immune Monitoring Center, Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ioannis S VlachosBeth Israel Deaconess Medical Center, Boston, MA, USA.
Manoj BhasinDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5M
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5M
Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTERU2CCA233303 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2018 to 2023
$9.7M
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8M
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9M
BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3M
Deep Discovery and Clinical Interpretation of Germline and Somatic Cancer DriversU24CA211006 · NCI · WASHINGTON UNIVERSITY · PI DING, LI, GOVINDAN, RAMASWAMY · 2016 to 2020
$1.8M
NCATS NIH HHS UL1 TR004419NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA196521NCI NIH HHS P50 CA186781NCI NIH HHS R35 CA210084NCI NIH HHS R50 CA211466NCI NIH HHS U24 CA211006NCI NIH HHS U24 CA224319NCI NIH HHS U2C CA233303NIDDK NIH HHS U01 DK124165
6 · The paper itself

Abstract

Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We established a harmonized consortium to generate an Immune Atlas of MM aimed at informing disease etiology, risk stratification, and potential therapeutic strategies. We generated a transcriptome profile of 1,149,344 single cells from the bone marrow of 263 newly diagnosed patients enrolled in the CoMMpass study and characterized immune and hematopoietic cell populations. Associating cell abundances and gene expression with disease progression revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing patients. Furthermore, signaling analyses suggested active intercellular communication involving APRIL-BCMA, potentially promoting tumor growth and survival. Finally, we demonstrate that integrating immune cell levels with genetic information can significantly improve patient stratification.

Indexed as

Bone Marrow MicroenvironmentInflammationMultiple MyelomaSenescenceSingle-CellTranscriptome

Identifiers

PMID38798338
PMCPMC11118283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.